Does nicotine affect D2 receptor upregulation? A case-control study

Acta Psychiatrica Scandinavica

Volumn 109, Issue 4, 2004, Pages 313-317

  Silvestri, S ^a   Negrete, J C ^b   Seeman, M V ^a   Shammi, C M ^a   Seeman, P ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

D2 receptor upregulation; Human PET study; Nicotine

Indexed keywords

CARBON 11; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; NICOTINE; RACLOPRIDE;

ADULT; AMENORRHEA; ARTICLE; CASE REPORT; DISEASE SEVERITY; DOSE RESPONSE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; MOTOR DYSFUNCTION; PARKINSONISM; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR SENSITIVITY; RECEPTOR UPREGULATION; SMOKING; TARDIVE DYSKINESIA; TONGUE DISEASE; TORTICOLLIS;

ADULT; ANIMALS; BRAIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; NICOTINE; RATS; RECEPTORS, DOPAMINE D2; SMOKING; TOMOGRAPHY, EMISSION-COMPUTED; UP-REGULATION;

EID: 1642523514     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2004.00293.x     Document Type: Article

References (35)

1. SEE RE, CHAPMAN MA. The consequences of long-term antipsychotic drug administration on basal ganglia neuronal function in laboratory animals. Crit Rev Neurobiol 1994;8:85-124.
2. TARSY D, BALDESSARINI RJ, TARAZI FI. Effects of newer antipsychotics on extrapyiramidal function (Review). CNS Drugs 2002;16:23-45.
3. SEEMAN P. Tardive dyskinesia, dopamine receptors, and neuroleptic damage to cell membranes. J Clin Psychopharmacol 1988;8(Suppl. 4):3S-9S.
4. FARDE L, WIESEL F-A, HALLDIN C et al. D2-dopamine receptor characteristics in neuroleptic-naïve patients with schizophrenia. Arch Gen Psychiatry 1990;47:213-219.
5. CAMBON H, BARON C, BOULENGER JP, LOOH C, ZARIFIAN E, MAZIERE B. In vivo assay for neuroleptic receptor binding in the Striatum: positron tomography in humans. Br J Psychiatry 1987;151:824-830.
6. SMITH M, WOLF AP, BRODIE JD et al. Serial [18F] methyl-spiroperidol PET studies to measure changes in antipsychotic drug D2 occupancy in schizophrenic patients. Biol Psychiatry 1988;23:653-663,
7. BARON JC, MARTINOT JL, CAMBON H et al. Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology 1989;99:463-472.
8. SILVESTRI S, SEEMAN MV, NEGRETE JC et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 2000;152:174-180.
9. HOULE S, KAPUR S, HUSSEY D, DASILVA JN, WILSON AA. Measurement of [11C] raclopride binding using a bolus plus infusion protocol. In: MYERS R, ed. Quantification of brain function using PET. Washington, DC: Academic Press, 1996:262-265.
10. KAY SR, FISZBEIN A, OPLER LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
11. SIMPSON GM, ANGUS JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;212:11-19.
12. GUY W. Abnormal involuntary movement scale (AIMS). In: GUY W., ed. ECDEU Assessment manual for psychopharmacology, revised 1976. Rockville, MD: PHS-ADAMHA, DHEW Publication (ADM), 1976:76-338, 534-537.
13. ALLEN R, LANE J, BRAUCHI J. Amantadine reduces haloperidol-induced dopamine receptor hypersensitivity in the striatum. Eur J Pharmacol 1980;65:313-315.
14. FRIEDHOFF A, BONNET K, ROSENGARTEN H. Reversal of two manifestations of dopamine receptor supersensitivity by administration of levodopa. Res Commun Chem Pathol Pharmacol 1977;16:411-423.
15. CARVEY PM, KAO LC, ZHANG TJ et al. Dopaminergic alterations in cotreatments attenuating haloperidol-induced supersensitivity. Pharmacol Biochem Behav 1990;35:291-300.
16. PERT A, ROSENBLATT JE, SIVIT C, PERT CB, BUNNEY WE Jr. Long-term treatment with lithium prevents the development of dopamine receptor supersensitivity. Science 1978;201:171-173.
17. ISHIKANE T, KUSUMI I, MATSUBARA R, MATSUBARA S, KOYAMA T. Effects of serotonergic agents on the up-regulation of dopamine D2-dopamine receptors induced by haloperidol in rat striatum. Eur J Pharmacol 1997;321:163-169.
18. PRASAD CH, SPAHN S, IKEGAMI H. Chronic nicotine blocks haloperidol-induced increase in striatal D2 dopamine receptor density. Biochem Biophys Res Commun 1989; 159:48-52.
19. JANSON AN, HEDLUND PB, FUXE K, VON EULER G. Chronic nicotine treatment counteracts dopamine D2 receptor up-regulation induced by partial meso-diencephalic hemitransection in the rat. Brain Res 1994;655:25-32.
20. JESTE DV, CALIGIURI MP. Tardive dyskinesia. Schizophr Bull 1993;19:303-315.
21. AINSWORTH K, SMITH SE, SHARP T. Repeated administration of fluoxetine, desipramine and tranylcypromine increases dopamine D2-like but not D1-like receptor function in the rat. J Psychopharmacol 1998;12:252-257.
22. CARVEY PM, KAO CM, TANNER CM, GOETZ CG, KLAWANS HL. The effect of antimuscarinic agents on haloperidol-induced behavioral supersensitivity. Eur J Pharmacol 1986;12:193.
23. MENZA MA, GROSSMAN N, VAN HORN M, CODY R, FORMAN N. Smoking and movement disorders in psychiatric patients. Biol Psychiatry 1991;30:109-115.
24. YASSA R, JESTE DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 1992;18:701-715.
25. PANDURANGI AK, ADERIBIGBE YA. Tardive dyskinesia in non-western countries: a review. Eur Arch Psychiatry Clin Neurosci 1995;246:47-52.
26. LAI IC, LIAO DL, BAI YM et al. Association study of the estrogen receptor polymorphisms with tardive dyskinesia in schizophrenia. Neuropsychobiology 2002;46:173-175.
27. YASSA R, LAL S, KORPASSY A, ALLY J. Nicotine exposure and tardive dyskinesia. Biol Psychiatry 1987;22:67-72.
28. NILSSON A, WALLER L, ROSENOREN A, ADLERBERTH A, WILHEMSEN L. Cigarette smoking is associated with abnormal involuntary movements in the general male population - a study of men born in 1933. Biol Psychiatry 1997;41:717-723.
29. CHONG SA, TAN EC, TAN CH. Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene. J Psychiatry Neurosci 2003;28:185-189.
30. ELLINGROD VL, SCHULZ SK, ARNDT S. Abnormal movements and tardive dyskinesia in smokers and non-smokers with schizophrenia genotyped for cytochrome P450 2D6. Pharmacotherapy 2002;22:1416-1419.
31. DALACK GW, HEALY DJ, MEADOR-WOODRUFF JH. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry 1998;155:1490-1501.
32. GOFF DC, HENDERSON DC, AMICO E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side-effects. Am J Psychiatry 1992;149:1189-1194.
33. SANDYK R. Cigarette smoking: effects on cognitive functions and drug-induced parkinsonism in chronic schizophrenia. Int J Neurosci 1993;70:193-197.
34. DECINA P, CARACCI G, SANDYK R, BERMAN W, MUKHERJEE S, SCAPICCHIO P. Cigarette smoking and neuroleptic-induced parkinsonism. Biol Psychiatry 1990;28:502-508.
35. SILVER AA, SHYTLE RD, PHILIPP MK, WILKINSON BJ, MCCONVILLE B, SANBERG PR. Transdermal nicotine and haloperidol in Tourette's disorder: a double-blind placebo-controlled study. J Clin Psychiatry 2001;62:707-714.